How are you testing your NASH patients?

Watch our interview with Dr. Arun Sanyal

ELF Physician Brochure
  • The Enhanced Liver Fibrosis (ELF) Test is the first routine, standardized, direct-biomarker panel for prognostic risk assessment in patients with advanced fibrosis due to NASH.
  • ELF is the first and only in vitro diagnostic to be granted De Novo Marketing Authorization by the FDA for prognosis of patients with advanced fibrosis due to NASH.
  • The widely studied ELF Test can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker.

<p>Arun J. Sanyal, MD</p>

I consent to the processing of my personal data by Siemens Healthineers (Corporate Information) for the purpose described above. I am aware further information can be found in the Data Privacy Policy and that I can partially or completely revoke this consent at any time through a declaration sent to
Subscription Button Icon
Be the first to know about our events, training, and news